And I'd consider that increase in valuation somewhat low if the drug is capable of doing what it's supposed to. $1 billion? If AGN licenses the drug for stroke in the American market, I'd be confident they could attain $2 billion+ valuation with significant royalties. I'm thinking at least 20-25% such is the potential upside. If she's talking about the value increasing 10 fold due to the inflection point reached post Phase 2 top line data results, that's probably more on the money.
Encouraging to hear Liz thinks they are still on track for an 18 month duration for the trial.
And I'd consider that increase in valuation somewhat low if...
Add AGN (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
79.0¢ |
Change
0.010(1.28%) |
Mkt cap ! $100.4M | |||
| Open | High | Low | Value | Volume |
| 78.0¢ | 80.5¢ | 78.0¢ | $71.40K | 90.43K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 15000 | 78.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 80.5¢ | 2444 | 1 |
View Market Depth
| Last trade - 15.55pm 23/08/2024 (20 minute delay) ? |
| AGN (ASX) Chart |